Biological Information | |
---|---|
Background Information: | The Ready-to-Assay™ α2A Adrenergic Receptor Frozen Cells are a simple, thaw-and-assay cell format for use in studying drug candidates (small molecules or biologics) targeting GPCRs. This assay assesses ligand (e.g. epinephrine and norepinephrine) based activation of ADRA2A GPCR activity via detection of increasing levels of intracellular calcium. The included cells overexpress ADRA2A alongside endogenous high levels of a promiscuous G-protein, coupling the receptor to the calcium signaling pathway. Upon activation of ADRA2A , the resulting calcium activity can be fluorescently assayed. Ready-to-assay kits consist of two vials of the stably modified clonal cell line in a convenient thaw-and-use format. |
Target Class: | GPCR |
Family: | Adrenoceptor |
Accession Number: | NM_000681 |
Target Name: | ADRA2A (α2A-adrenoceptor) |
Target Aliases: | ADRA2, ADRA2R, ADRAR, ALPHA2AAR, ZNF32, Adrenergic receptor alpha 2A, ADRA2A, α2A, Adrenoceptor |
Target Species: | Human |
Usage | |
Product Type: | Frozen Cells |
Application: | Drug Discovery & Development |
Storage Conditions: | Short term (24 h) in vapor phase of liquid nitrogen. Media at 4°C. |
Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Assay Information | |
Assay Measures: | Calcium Flux |
Detection Method: | Fluorescence |
Additional Information | |
Brand: | ChemiSCREEN™ |
Ready-to-Assay™ alpha2A Adrenergic Receptor Frozen Cells
The Ready-to-Assay™ α2A Adrenergic Receptor Frozen Cells measure ADRA2A (GPCR) activation via an increase in intracellular calcium. Ready-to-Assay kits contain two vials of thaw-and-use cells.
User Manuals & Protocols
70-427 ChemiSCREEN and ChemiBRITE Cell Lines User Manual REV1
View DocumentDatasheets
HTS096RTA Datasheet
View Document